Audit: QRS - KPV for Health & Longevity
Audit conducted on 30/09/2026 07:50 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 88 |
| Failed | 0 |
| N/A | 6 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS statements (at-a-glance, protocol cells, time to effect, tiers, gates, monitoring) trace to ER text (Motivation, Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions & Contraindications, Monitoring, Conclusion). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious phrasing kept: “has never been tested in a human trial”, “No dose of KPV has been tested in humans”, “no KPV human data exist”, “(theoretical)”, “may depend on damaged or inflamed skin”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No claim strengthened or softened; contraindications and interaction tiers mirror ER. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Each item is surfaced under its ER category (contraindications from avoid-list, interactions from interaction bullets, tiers from benefit/risk sections). |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only ER-named drugs/peptides (methotrexate, BPC-157, KdPT, etc.) appear; no PMIDs, NCTs, or experts added. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-first tone consistent with ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert yet accessible; neutral and data-driven. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents protocols as circulating practice (“some protocols escalate”), not prescriptions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advisory wording; dosing framed as approaches with evidence caveat. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Presents information; no “recommend”/”should” wording. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No direct address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language; technical terms limited to ER labels, marker names and thresholds needed for decision gates; “peptide” and “excipients” explained. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact list/cell format. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | At-a-glance frames for “health-focused adults targeting long-lasting inflammation”. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monitoring cadence, labs and course structure suit an effort-willing audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not framed for the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting reflects the proactive audience (experimental short-course option, supply and diagnosis risks). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal terms used (“Oral”, “Subcutaneous”, “injection”); no lay route phrasing. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed headings, gate headings, tier labels, and table headers unchanged. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans present (marker_# and qualitative_item_# expanded to 1-5). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against template shows only variable content and permitted display:none changes. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No QRS section rendered empty; empty ER tiers (Benefits High/Medium, Risks High/Medium/Low) are hidden per 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Oral (gut-focused) approach”, “Subcutaneous (systemic) approach”, “Topical approach”) and qualitative labels match ER bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels are ER-derived; time-to-effect labels use ER wording (“gut-symptom”, “KdPT analog … ulcerative colitis”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in QRS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed (rationales, definitions and effect details stripped) to a single-sheet layout. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment directly follows <!doctype html> (line 2). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — lines. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only duration quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: kpv_2026-0930-0640_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.29 matches QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0930-0734 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5.5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname + version only. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the file name. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed and correctly quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “KPV for Health & Longevity - Quick Reference Sheet” |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “KPV for Health & Longevity” |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/30/2026 matches qrs_creation_date. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | No extra header content. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “KPV, a peptide (three linked protein building blocks) cut from a natural hormone, is offered for gut and skin inflammation” before the evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses Conclusion: animal-only benefit, no human trial, supply and diagnosis risks, experimental short-course verdict. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to Motivation or Conclusion passages. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “peptide” explained in plain words. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trials cited. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER “Populations who should avoid KPV”. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 9 ER populations listed. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationales (e.g., WADA reason, “no reproductive safety data”) stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers kept: “Mayo score ≥6”, “eGFR <30 mL/min/1.73 m²”, “in place of standard therapy”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names populations to avoid. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER interaction bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 7 ER interactions listed; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanisms and mitigations stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved; “(theoretical)” qualifier kept for vaccination. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated; ER names interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | From ER Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Oral, subcutaneous, topical approaches are the three ER actionable routes. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three actionable aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three cells filled with ER-derived dose, route and caveat content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | ER gives two time-to-effect aspects (KdPT UC at 2 weeks; gut symptoms 1-4 weeks); both used. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Controlled-trial signal (KdPT, 2 weeks) placed before clinic reports for the same intestinal-inflammation benefit. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | Third time cell empty and hidden with display: none. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used sets filled with ER-derived content. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | From ER Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items reduced to ER headings. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(Inflammaging)” stripped; no parentheticals. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High and Medium spans set to display: none. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | From ER Potential Risks & Side Effects. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items reduced to ER headings (Immunogenicity rendered in plain words). |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High, Medium and Low spans set to display: none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | From ER Monitoring Protocol table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 5 ER biomarkers listed with ER ranges and reasons. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated from ER Ongoing monitoring. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | From ER Qualitative markers. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 5 qualitative markers listed verbatim. |
Issues 30/09/2026 07:50
Pass rate 100.00%. No issues found.
Issues 30/09/2026 07:47
- 2.13 — At a Glance lacks audience framing: The At a Glance text (QRS line 433) omits the ER Conclusion’s audience-specific verdict (“For this audience, KPV is an experimental, short-course anti-inflammatory option…”) and the appeal to health-focused adults seeking to lower long-lasting inflammation, ending with a generic “It remains an experimental, short-course option.”
Fixes 30/09/2026 07:47
- 2.13 — At a Glance audience framing: Replaced the closing “It remains an experimental, short-course option.” with “For health-focused adults targeting long-lasting inflammation, it is an experimental, short-course option with unknown long-term risk.” (per the ER Conclusion), trimming elsewhere to stay at 70 words.
Issues 30/09/2026 07:44
- 2.7 — Unexplained jargon in risks: The Risks Speculative list (line 586) uses the specialist term “immunogenicity” instead of plain wording, although the ER explains it as the risk of provoking antibodies or immune reactions.
Fixes 30/09/2026 07:44
- 2.7 — Unexplained jargon in risks: Replaced “immunogenicity” in the Risks Speculative list with the ER-supported plain wording “antibody or immune reactions to the peptide”.
Issues 30/09/2026 07:39
- 7.2 — Missing execution-oriented bottom line: The At a Glance text (QRS line 433) condenses Conclusion paragraphs 1-2 but omits the Conclusion’s decision-relevant takeaway (ER line 382) that KPV is an experimental, short-course option with unproven human benefit and unknown long-term risk.
Fixes 30/09/2026 07:39
- 7.2 — Added execution-oriented bottom line: Appended “It remains an experimental, short-course option.” to At a Glance (from ER Conclusion) and shortened the peptide gloss to “(three linked protein building blocks)” to stay within 70 words.
Issues 30/09/2026 07:36
- 2.7 — Unexplained jargon “excipients”: The Contraindications item “Known hypersensitivity to KPV or product excipients” (QRS line 549) uses the pharmaceutical term “excipients” without the plain-language gloss “(inactive ingredients)” that the ER supplies (ER line 272).
Fixes 30/09/2026 07:36
- 2.7 — Glossed jargon “excipients”: Changed the Contraindications item from “Known hypersensitivity to KPV or product excipients” to “Known hypersensitivity to KPV or product excipients (inactive ingredients)”, using the ER’s own gloss.